Alirocumab: First Global Approval

Drugs

Volumn 75, Issue 14, 2015, Pages 1699-1705

  Markham, Anthony ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EZETIMIBE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SUBTILISIN; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ARTICLE; BRONCHITIS; CARDIOVASCULAR RISK; CONTUSION; CORONARY ARTERY ATHEROSCLEROSIS; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; GOOD CLINICAL PRACTICE; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INFLUENZA; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MONOTHERAPY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NUMMULAR DERMATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; INTERNATIONAL COOPERATION;

ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG APPROVAL; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INTERNATIONALITY;

EID: 84942500745     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0469-8     Document Type: Article

References (24)

1. FDA. FDA approves Praluent to treat certain patients with high cholesterol [media release]. 24 July 2015. www.fda.gov.
2. European Medicines Agency. Praluent (alirocumab) - summary of opinion. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/003882/WC500190416.pdf. Accessed 1 Sept 2015.
3. Sanofi-aventis, Regeneron Pharmaceuticals Inc. Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 % [media release]. 3 Dec 2007. http://en.sanofi.com.
4. Sanofi-aventis. Sanofi-aventis and Regeneron expand strategic antibody collaboration [media release]. 12 Nov 2009. http://en.sanofi.com.
5. Sanofi-aventis, Regeneron Pharmaceuticals Inc. Sanofi and Regeneron announce collaboration with American College of Cardiology for PCSK9 inhibitor clinical program [media release]. 19 Dec 2013. http://investor.regeneron.com.
6. McKenney J, Swergold G, DiCioccio T, et al. Dynamics between the monoclonal antibody sar236553/regn727, proprotein convertase subtilisin/kexin type 9 (Pcsk9) and low-density lipoprotein cholesterol (LDL-C) Levels (Funding: Regeneron/Sanofi) [abstract no. 298]. In: European Atherosclerosis Society Annual Congress. 2013.
7. Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297-301.
8. Regeneron Pharmaceuticals Inc, Sanofi-aventis. PRALUENT (alirocumab): US prescribing Information. 2015.
9. Rey J, Poitiers F, Paehler T, et al. Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, administered every 4 weeks alone or in combination with ezetimibe or fenofibrate in healthy subjects [abstract no. 1183-131]. J Am Coll Cardiol. 2014;63(12 Supplement):A1375.
10. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-15.e13.
11. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186-94.
12. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99.
13. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140-8.
14. Bays H, Farnier M, Gaudet D, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II [abstract]. Circulation. 2015;130(23):2118-9.
15. Roth E, Rader DJ, Moriarty P. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [abstract no. 0254]. In: 17th International Symposium on Atherosclerosis. 2015.
16. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-53.
17. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891-900.
18. Teramoto T, Kobayashi M, Uno K, et al. Efficacy and safety of alirocumab in Japanese patients with hypercholesterolemia on stable statin therapy: first data with the 75 mg every two weeks dose [abstract no. 13651]. In: 87th Annual Scientific Sessions of the American Heart Association. 2014.
19. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55-61.
20. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Circulation. 2014;130(23):2108-9.
21. Stroes E, Guyton J, Farnier M. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [abstract no. 0269]. In: 17th International Symposium on Atherosclerosis. 2015.
22. Kastelein JJ, Robinson JG, Farnier M. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies [abstract no. 2125]. In: European Society of Cardiology. 2015.
23. Ginsberg HN, Rader DJ, Raal FJ. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation. 2014;130(23):2119.
24. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36.